Gene:
ATP5F1
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA25130

Details

Cytogenetic Location: chr1 : p13.2 - p13.2
GP mRNA Boundary: chr1 : 111991743 - 112004540
GP Gene Boundary: chr1 : 111981743 - 112007540
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Doxorubicin Pathway (Cardiomyocyte Cell), Pharmacodynamics
    Representation of the candidate genes involved in adverse effects of doxorubicin in a stylized cardiomyocyte.

External Pathways

Links to non-PharmGKB pathways.

  1. Formation of ATP by chemiosmotic coupling - (Reactome via Pathway Interaction Database)

Publications related to ATP5F1: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
New developments in anthracycline-induced cardiotoxicity. Current medicinal chemistry. 2009. Mordente A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proceedings of the National Academy of Sciences of the United States of America. 1988. Olson R D, et al. PubMed

LinkOuts

Entrez Gene:
515
OMIM:
603270
UCSC Genome Browser:
NM_001688
RefSeq RNA:
NM_001688
RefSeq Protein:
NP_001679
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NT_032977
NW_001838594
NW_922462
UniProtKB:
AT5F1_HUMAN (P24539)
Q08ET0_HUMAN (Q08ET0)
Ensembl:
ENSG00000116459
GenAtlas:
ATP5F1
GeneCard:
ATP5F1
MutDB:
ATP5F1
ALFRED:
LO079526D
HuGE:
ATP5F1
Comparative Toxicogenomics Database:
515
ModBase:
P24539
HumanCyc Gene:
HS04013
HGNC:
840

Common Searches